이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

genedrive 과거 수익 실적

과거 기준 확인 0/6

genedrive은 연평균 13.1%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 연평균 19.6%의 비율로 수입이 증가했습니다. 매출은 연평균 57%의 비율로 감소했습니다.

주요 정보

13.1%

수익 성장률

38.2%

EPS 성장률

Life Sciences 산업 성장	36.9%
매출 성장률	-57.0%
자기자본 수익률	-331.9%
순이익	-1,837.5%
최근 수익 업데이트	31 Dec 2023

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

genedrive 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

AIM:GDR 수익, 비용 및 수입 (GBP Millions )
날짜	수익	수익	G+A 비용
31 Dec 23	0	-5	1
30 Sep 23	0	-5	1
30 Jun 23	0	-5	1
31 Mar 23	0	-5	1
31 Dec 22	0	-5	2
30 Sep 22	0	-5	2
30 Jun 22	0	-5	2
31 Mar 22	0	-4	2
31 Dec 21	0	-4	2
30 Sep 21	1	-2	2
30 Jun 21	1	-1	2
31 Mar 21	1	-8	2
31 Dec 20	1	-15	2
30 Sep 20	1	-17	2
30 Jun 20	1	-19	2
31 Mar 20	1	-12	2
31 Dec 19	2	-5	2
30 Sep 19	2	-4	2
30 Jun 19	2	-4	2
31 Mar 19	2	-5	2
31 Dec 18	2	-7	2
30 Sep 18	2	-7	2
30 Jun 18	2	-7	2
31 Dec 17	1	-6	3
30 Sep 17	2	-6	3
30 Jun 17	3	-7	3
31 Mar 17	6	-6	2
31 Dec 16	6	-5	2
30 Sep 16	6	-6	2
30 Jun 16	5	-6	2
31 Mar 16	5	-5	2
31 Dec 15	4	-5	2
30 Sep 15	4	-4	2
30 Jun 15	5	-3	2
31 Mar 15	5	-3	2
31 Dec 14	5	-3	2
30 Sep 14	5	-2	2
30 Jun 14	6	-2	2
31 Mar 14	5	-2	2
31 Dec 13	5	-1	2
30 Sep 13	5	-1	1

양질의 수익: GDR 은(는) 현재 수익성이 없습니다.

이익 마진 증가: GDR 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: GDR 은(는) 수익성이 없지만 지난 5년 동안 연간 13.1% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 GDR 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: GDR 은(는) 수익성이 없어 지난 해 수익 성장을 Life Sciences 업계( -1.7% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: GDR 현재 수익성이 없기 때문에 마이너스 자본 수익률( -331.87% )을 갖습니다.

genedrive 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

genedrive plc to Report First Half, 2024 Results on Mar 28, 2024

Full year 2023 earnings released: UK£0.055 loss per share (vs UK£0.055 loss in FY 2022)

genedrive plc to Report Fiscal Year 2023 Results on Nov 30, 2023

Full year 2022 earnings released: UK£0.055 loss per share (vs UK£0.012 loss in FY 2021)

genedrive plc to Report Fiscal Year 2022 Results on Nov 21, 2022

First half 2022 earnings released

Recent updates

Genedrive plc Receives Breakthrough Device Designation from the U.S. Food and Drug Administration

genedrive plc has completed a Follow-on Equity Offering in the amount of £6 million.

New major risk - Shareholder dilution

genedrive plc has filed a Follow-on Equity Offering in the amount of £3.5 million.

New major risk - Shareholder dilution

genedrive plc to Report First Half, 2024 Results on Mar 28, 2024

New major risk - Market cap size

genedrive plc, Annual General Meeting, Dec 29, 2023

New major risk - Share price stability

Full year 2023 earnings released: UK£0.055 loss per share (vs UK£0.055 loss in FY 2022)

New major risk - Market cap size

genedrive plc to Report Fiscal Year 2023 Results on Nov 30, 2023

New minor risk - Financial data availability

genedrive plc Announces Chief Executive Officer Changes

Genedrive plc Achieves UKCA Marking Registration for its New Genedrive CYP2C19 System

Is genedrive (LON:GDR) In A Good Position To Invest In Growth?

genedrive plc, Annual General Meeting, Dec 29, 2022

Full year 2022 earnings released: UK£0.055 loss per share (vs UK£0.012 loss in FY 2021)

genedrive plc to Report Fiscal Year 2022 Results on Nov 21, 2022

genedrive plc Files US FDA Pre-Submission for the Genedrive® MT-RNR1 Product Range

Genedrive plc Announces UK's National Institute for Health and Clinical Excellence Commences an Evaluation of CYP2C19 Genotype Testing for Clopidogrel Treatment

Here's Why We're Watching genedrive's (LON:GDR) Cash Burn Situation

NICE to Evaluate the Genedrive MT-RNR1 Test

High number of new directors

Genedrive plc Announces Point-Of-Care Cov19-Id Kit Receives CTDA Approval from Medicines and Healthcare Products Regulatory Agency

High number of new directors

Now 25% undervalued after recent price drop

First half 2022 earnings released

Genedrive plc Announces NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test

genedrive plc Announces Resignation of Matthew Fowler as Group's Chief Financial Officer

Genedrive plc Provides Update on Point of Care Covid Test

genedrive plc to Report First Half, 2022 Results on Mar 29, 2022

genedrive plc Announces UK CTDA application for Point-of-Care Genedrive®?COV19-ID kit

Full year 2021 earnings released: UK£0.012 loss per share (vs UK£0.55 loss in FY 2020)

Insufficient new directors

We're A Little Worried About genedrive's (LON:GDR) Cash Burn Rate

Genedrive COVID-19 Point of Care device update

Here's Why genedrive (LON:GDR) Must Use Its Cash Wisely

First half 2021 earnings released: EPS UK£0.019 (vs UK£0.089 loss in 1H 2020)

New 90-day high: UK£1.49

genedrive plc Enters Distribution Agreement with Mountain Horse Solutions

genedrive plc Provides an Update on its Antibiotic Induced Hearing Loss Assay

New 90-day high: UK£0.98

genedrive plc Enters into Distribution Agreement with Beckman Coulter Life Sciences

Is genedrive's (LON:GDR) Share Price Gain Of 252% Well Earned?

genedrive plc to Report First Half, 2021 Results on Mar 25, 2021

New 90-day low: UK£0.42

genedrive plc, Annual General Meeting, Dec 30, 2020

New 90-day low: UK£0.49

Genedrive plc Announces Successful Completion of the Antibiotic Induced Hearing Loss Implementation Study

Full year 2020 earnings released: UK£0.55 loss per share

Earnings beat expectations, revenue disappoints

Genedrive Announces HCV ID Kit Demonstrates High Clinical Accuracy in India Study

Full year 2020 earnings released: UK£0.55 loss per share

Earnings beat expectations, revenue disappoints

New 90-day low: UK£0.68

genedrive plc to Report Fiscal Year 2020 Results on Nov 17, 2020

genedrive plc Announces South African Approval

genedrive plc Announces Completes Initial Testing of Beckman Coulter Life Sciences' Rnadvance Viral RNA

New 90-day high: UK£1.34

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기